Health Executive Insights
Jamie Stanistreet
Retired Managing Director Medtronic Australia and New Zealand
talks Medical Technology in Australia and the Asia-Pacific
▶︎ Career turning points
▶︎ Current industry roles
▶︎ Innovation hurdles
▶︎ Asia-Pacific health market
▶︎ Trends in patient centricity
▶︎ Opportunity for MedTech
▶︎ Showing value of new technology
▶︎ Timely access to treatment
You Might also like
-
World-first clinical trial improves patient outcomes for kidney transplants
A world-first clinical trial conducted at the Royal Adelaide Hospital (RAH) and at hospitals across Australia and New Zealand has identified the best fluid treatment to reduce the risk of patients requiring dialysis after a kidney transplant.
Australian Health Journal spoke with the lead-author of the study, RAH Nephrologist and University of Adelaide researcher, Dr Michael Collins.
-
Clinical entrepreneur addresses needle-phobia
Australian entrepreneur, Lauren Barber, turned her nursing background into the role of an inventor and launched a medical device into the Australian healthcare industry.
No journey is linear for an entrepreneur, but Lauren has travelled considerable distance from a nursing student to a successful entrepreneur illustration her determination and passion to help those with needle phobias. Lauren’s work with NeedleCalm is making a positive impact in the healthcare industry and improving the experiences of patients and clinicians alike.
-
Medicinal cannabis in Australia Update
According to the Australian Journal of General Practice, published by the Royal Australian College of General Practitioners, more than 130,000 medicinal cannabis approvals have been issued in Australia to date, mostly by general practitioners, with approximately 65% of these to treat chronic non-cancer pain. Despite robust supportive data from animal models, current clinical trial evidence for THC and CBD efficacy in chronic pain is incomplete. In their prescribing decisions, doctors must balance patient demand and curiosity with caution regarding potential risks and limited efficacy.
Australian Health Journal met with 3 speakers at the recent ARCS22 Conference providing an update on medicinal cannabis. The discussion with the speakers now centres on affordability and access.